Fed. Circ. Eyes Eligibility Of Stanford's Transplant Testing IP

By Khorri Atkinson · June 10, 2022, 9:10 PM EDT

Two Federal Circuit judges did not seem fully convinced Friday that three Stanford University patents licensed to CareDx Inc., developer of commercial tests for kidney transplant rejections, are valid under the...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

CareDx, Inc. v. Natera, Inc.

Case Number

22-1027

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

October 08, 2021